Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors

[1] Mok TS(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957

[2] Wu YL(2007)Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies Drug Resist Updat 10 81-100

[3] Thongprasert S(2004)Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions Carcinogenesis 25 2053-2059

[4] Yang CH(2006)Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 5165-5173

[5] Chu DT(2001)Regulation of translation initiation by FRAP/mTOR Genes Dev 15 807-826

[6] Saijo N(2006)Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway Anticancer Drugs 17 487-494

[7] Sunpaweravong P(2008)Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs Br J Cancer 98 923-930

[8] Han B(1994)Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J Natl Cancer Inst 86 1517-1524

[9] Margono B(2007)Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma Leukemia 21 333-339

[10] Ichinose Y(2006)Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer Clin Cancer Res 12 7099-7107

[1] Mok TS(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957

[2] Wu YL(2007)Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies Drug Resist Updat 10 81-100

[3] Thongprasert S(2004)Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions Carcinogenesis 25 2053-2059

[4] Yang CH(2006)Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 5165-5173

[5] Chu DT(2001)Regulation of translation initiation by FRAP/mTOR Genes Dev 15 807-826

[6] Saijo N(2006)Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway Anticancer Drugs 17 487-494

[7] Sunpaweravong P(2008)Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs Br J Cancer 98 923-930

[8] Han B(1994)Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J Natl Cancer Inst 86 1517-1524

[9] Margono B(2007)Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma Leukemia 21 333-339

[10] Ichinose Y(2006)Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer Clin Cancer Res 12 7099-7107